Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7295 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD7295 | DRUG | ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution |
| Placebo | DRUG | multiple ascending dose (tbd based on single dose results), oral solution |
Inclusion Criteria: * Provision of signed, written and dated informed consent * Healthy male Japanese volunteers aged 20-55 years * BMI between 18 and 27 kg/m2 * Have negative screens for HIV, hepatitis B and C viruses and syphilis Exclusion Criteria: * Use of prescribed medication within 2 weeks...
AZD7295 is an investigational small molecule drug developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy Japanese male subjects. The specific disease or condition it is intended to treat has not been disclosed.
AZD7295 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the Phase 1 trial of the compound conducted in Japan.
AZD7295 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
AZD7295 has been evaluated in one completed Phase 1 trial, NCT00818129, titled a study to investigate safety, tolerability and pharmacokinetics following single and multiple ascending doses in Japanese subjects. The trial enrolled 62 healthy male volunteers in Japan and was placebo-controlled, randomized, and double-blind.
The Phase 1 trial NCT00818129 evaluated the safety, tolerability, and pharmacokinetics of AZD7295 after single and multiple ascending doses in healthy Japanese male subjects. It enrolled 62 participants, was randomized, double-blind, and placebo-controlled, and has been completed.